News Policy

Anti-Cannabis Groups Sue New York Over Legalization

Anti-Cannabis New-York
Written by PsychePen

Anti-cannabis groups have filed a lawsuit to overturn New York’s cannabis legalization law, citing federal law and arguing that lawmakers bypassed Congress. The outcome could set a precedent for other states.

Summary: Anti-cannabis advocates, including the Cannabis Impact Prevention Coalition and the Cannabis Industry Victims Seeking Justice, have filed a lawsuit in the New York Supreme Court to overturn the state’s cannabis legalization law. The lawsuit cites federal law, which still outlaws cannabis, and argues that New York lawmakers bypassed Congress when they passed the state’s cannabis legalization law. The outcome of this lawsuit could potentially set a precedent for other states that have legalized or are considering legalizing cannabis.


Keep Yourself Informed

Stay informed and up-to-date with the latest news from the Cannabis and Psychedelic industry.
Subscribe below for updates.


Anti-Cannabis Advocates File Lawsuit to Overturn New York’s Legalization Law

In a surprising turn of events, anti-cannabis advocates, including the Cannabis Impact Prevention Coalition and the Cannabis Industry Victims Seeking Justice, along with eight individuals associated with these groups, have filed a lawsuit in the New York Supreme Court. Their aim is to overturn the state’s cannabis legalization law, which was passed in 2021. The lawsuit cites federal law, which still outlaws cannabis, and argues that New York lawmakers bypassed Congress when they passed the state’s cannabis legalization law.

The groups contend that cannabis is harmful and its claims about its medical benefits are unfounded. They argue that false advertising may mislead vulnerable patients and the public. The lawsuit states, “Medical use may inadvertently result in addiction, increased risk of psychosis, mental or psychosocial impairment, lung damage when smoked, and complications for unborn children when used during pregnancy.” They also claim that the presence of medical marijuana dispensaries may increase access to recreational marijuana for minors.

The famous THCA loophole allowing everyone to get psychoactive hemp

The lawsuit further contends that claims about the medical benefits of THC and CBD have not been subjected to studies that satisfy the federal Food and Drug Administration’s standards for determining the efficacy of the products. The FDA has never approved a cannabis product even as a dietary supplement, they point out.

David G. Evans, a New Jersey attorney and organizer of the group Cannabis Industry Victims Seeking Justice, told the Times-Union that this is the first lawsuit of its kind in the U.S. The outcome of this lawsuit could potentially set a precedent for other states that have legalized or are considering legalizing cannabis.

We will follow closely the outcome of this lawsuit, as it could have significant implications for the future of cannabis legalization not only in New York but across the United States.

[Source: Ganjapreneur]

.

Subscribe to our newsletter

We hope you enjoyed this news update. Check back with us daily to see what’s going on in the world of cannabis and psychedelics. And make sure to subscribe to our Newsletter for all the latest in the industry!

Simply place your email below:

.

.

AI Disclaimer: This news update was created using AI tools. PsychePen is an AI author who is constantly improving. We appreciate your kindness and understanding as PsychePen continues to learn and develop. Please note that the provided information is derived from various sources and should not be considered as legal, financial, or medical advice.

Have anything to add? Your voice matters! Join the conversation and contribute your insights and ideas below.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

About the author

PsychePen

PsychePen is Cannadelics' main news editor. As a self-taught wellness expert with a unique perspective on drugs, cannabis, and psychedelics, PsychePen is known for his unique style: short and informative articles, easy-to-read and to-the-point. PsychePen is also one of our most successful AI authors. so its keep on improving.